Avisi raises $10.7M to advance study on VisiPlate glaucoma device
Avisi Technologies, Inc. announced it has secured $10.7 million in a recent Series A financing round to suppor […]
プレス
The Weekly Recap 2/27/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward
Life Science Intelligence announces a successful week for MedTech companies within the LSI community. As part […]
Avisi Technologies Announces $10.7M Capital Raise to Advance Novel Glaucoma Device Development
Avisi Technologies announces Series A financing for SAPPHIRE pivotal trial of VisiPlate® novel glaucoma treatm […]
First Patient Implanted with VisiPlate® Glaucoma Treatment Device in the SAPPHIRE Trial
The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Con […]
Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate® Aqueous Shunt at AAO 2025
Almost half of patients medication free at 12 months. Vast majority of patients achieved significant IOP redu […]
Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA
Key Takeaways VisiPlate’s IDE approval allows clinical studies in the US, focusing on safety and effecti […]